 Rohit Katial
Concepts (429)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 59 | 2025 | 1797 | 6.670 |
Why?
| | Anti-Asthmatic Agents | 26 | 2025 | 260 | 5.080 |
Why?
| | Hypersensitivity | 9 | 2024 | 254 | 2.720 |
Why?
| | Biological Products | 13 | 2025 | 257 | 2.670 |
Why?
| | Aspirin | 11 | 2018 | 406 | 2.460 |
Why?
| | Respiratory Tract Diseases | 6 | 2016 | 175 | 2.100 |
Why?
| | Rhinitis, Allergic, Perennial | 8 | 2018 | 20 | 2.060 |
Why?
| | Rhinitis, Allergic, Seasonal | 8 | 2012 | 25 | 2.030 |
Why?
| | Sinusitis | 11 | 2024 | 227 | 1.990 |
Why?
| | Adrenal Cortex Hormones | 16 | 2025 | 484 | 1.660 |
Why?
| | Rhinitis | 7 | 2024 | 169 | 1.490 |
Why?
| | Eosinophils | 17 | 2025 | 316 | 1.430 |
Why?
| | Nitric Oxide | 8 | 2024 | 892 | 1.330 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 7 | 2018 | 346 | 1.290 |
Why?
| | Nasal Polyps | 7 | 2024 | 59 | 1.250 |
Why?
| | Antibodies, Monoclonal, Humanized | 16 | 2024 | 992 | 1.210 |
Why?
| | Eosinophilic Esophagitis | 2 | 2024 | 332 | 1.210 |
Why?
| | Rhinitis, Allergic | 4 | 2024 | 42 | 1.200 |
Why?
| | Allergens | 7 | 2024 | 386 | 1.140 |
Why?
| | Immunoglobulin E | 7 | 2025 | 315 | 1.120 |
Why?
| | Eosinophilia | 7 | 2024 | 224 | 1.100 |
Why?
| | Skin Tests | 3 | 2024 | 94 | 1.070 |
Why?
| | Histamine Antagonists | 4 | 2011 | 21 | 1.050 |
Why?
| | Mast Cells | 3 | 2023 | 148 | 0.990 |
Why?
| | Cost of Illness | 3 | 2024 | 324 | 0.960 |
Why?
| | Exhalation | 2 | 2018 | 29 | 0.920 |
Why?
| | Anti-Allergic Agents | 4 | 2018 | 40 | 0.920 |
Why?
| | Desensitization, Immunologic | 4 | 2016 | 89 | 0.920 |
Why?
| | Immunologic Deficiency Syndromes | 3 | 2016 | 68 | 0.830 |
Why?
| | Humans | 116 | 2025 | 145750 | 0.830 |
Why?
| | Angioedema | 1 | 2024 | 16 | 0.820 |
Why?
| | Severity of Illness Index | 14 | 2025 | 2933 | 0.810 |
Why?
| | Urticaria | 1 | 2024 | 38 | 0.800 |
Why?
| | Immunotherapy | 5 | 2017 | 667 | 0.800 |
Why?
| | Mastocytosis | 1 | 2023 | 14 | 0.790 |
Why?
| | Proton Pump Inhibitors | 1 | 2024 | 109 | 0.780 |
Why?
| | Remission Induction | 6 | 2025 | 307 | 0.770 |
Why?
| | Gastritis | 1 | 2024 | 117 | 0.750 |
Why?
| | Enteritis | 1 | 2024 | 105 | 0.740 |
Why?
| | Deglutition Disorders | 1 | 2024 | 154 | 0.730 |
Why?
| | Biomarkers | 10 | 2025 | 4302 | 0.720 |
Why?
| | Allergy and Immunology | 2 | 2024 | 43 | 0.670 |
Why?
| | Pancreatitis | 2 | 2012 | 146 | 0.660 |
Why?
| | Albuterol | 3 | 2010 | 76 | 0.660 |
Why?
| | Androstadienes | 2 | 2010 | 77 | 0.630 |
Why?
| | Breath Tests | 4 | 2007 | 77 | 0.630 |
Why?
| | Patient Reported Outcome Measures | 1 | 2024 | 498 | 0.610 |
Why?
| | Sputum | 4 | 2024 | 302 | 0.610 |
Why?
| | Drug Hypersensitivity | 4 | 2016 | 90 | 0.570 |
Why?
| | Antibodies, Monoclonal | 4 | 2025 | 1505 | 0.560 |
Why?
| | Bronchial Provocation Tests | 3 | 2018 | 47 | 0.540 |
Why?
| | Biological Therapy | 1 | 2017 | 28 | 0.500 |
Why?
| | Adult | 46 | 2025 | 40867 | 0.480 |
Why?
| | STAT6 Transcription Factor | 1 | 2016 | 24 | 0.470 |
Why?
| | Insect Bites and Stings | 1 | 2016 | 13 | 0.470 |
Why?
| | Middle Aged | 36 | 2025 | 36297 | 0.430 |
Why?
| | Administration, Intranasal | 6 | 2011 | 94 | 0.430 |
Why?
| | Vaccination | 3 | 2012 | 1428 | 0.430 |
Why?
| | Practice Guidelines as Topic | 7 | 2024 | 1582 | 0.420 |
Why?
| | Anaphylaxis | 1 | 2016 | 102 | 0.420 |
Why?
| | Double-Blind Method | 10 | 2025 | 2064 | 0.400 |
Why?
| | Forced Expiratory Volume | 3 | 2018 | 450 | 0.390 |
Why?
| | Male | 44 | 2025 | 72992 | 0.370 |
Why?
| | Treatment Outcome | 20 | 2025 | 11793 | 0.370 |
Why?
| | Female | 46 | 2025 | 79025 | 0.360 |
Why?
| | Bronchial Hyperreactivity | 3 | 2018 | 104 | 0.350 |
Why?
| | T-Lymphocyte Subsets | 2 | 2009 | 420 | 0.350 |
Why?
| | Chronic Disease | 9 | 2024 | 1810 | 0.340 |
Why?
| | Disease Progression | 5 | 2023 | 2865 | 0.330 |
Why?
| | Young Adult | 14 | 2025 | 14250 | 0.330 |
Why?
| | Pulmonary Eosinophilia | 2 | 2022 | 27 | 0.320 |
Why?
| | Dermatitis, Atopic | 2 | 2024 | 322 | 0.310 |
Why?
| | Aged | 15 | 2025 | 26212 | 0.310 |
Why?
| | Acetates | 1 | 2010 | 78 | 0.300 |
Why?
| | Vaccines | 2 | 2004 | 389 | 0.290 |
Why?
| | Nose | 1 | 2009 | 67 | 0.280 |
Why?
| | Adolescent | 15 | 2025 | 22569 | 0.280 |
Why?
| | Quinolines | 1 | 2010 | 190 | 0.280 |
Why?
| | Laryngismus | 1 | 2008 | 10 | 0.270 |
Why?
| | Leukotriene E4 | 1 | 2008 | 24 | 0.270 |
Why?
| | Vocal Cords | 1 | 2008 | 27 | 0.270 |
Why?
| | Immunity, Cellular | 2 | 2007 | 274 | 0.270 |
Why?
| | United States | 7 | 2024 | 16122 | 0.270 |
Why?
| | Diagnosis, Differential | 5 | 2017 | 1512 | 0.250 |
Why?
| | Food Hypersensitivity | 2 | 2009 | 164 | 0.250 |
Why?
| | Gastrointestinal Diseases | 1 | 2009 | 222 | 0.240 |
Why?
| | Paranasal Sinuses | 2 | 2020 | 81 | 0.240 |
Why?
| | Quality of Life | 6 | 2025 | 3210 | 0.240 |
Why?
| | Ethyl Chloride | 1 | 2005 | 1 | 0.230 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2009 | 411 | 0.230 |
Why?
| | Matrix Metalloproteinase 9 | 3 | 2011 | 131 | 0.230 |
Why?
| | Respiratory Tract Infections | 2 | 2004 | 396 | 0.230 |
Why?
| | Mastocytosis, Systemic | 1 | 2005 | 6 | 0.220 |
Why?
| | Biosimilar Pharmaceuticals | 1 | 2025 | 28 | 0.220 |
Why?
| | Nebulizers and Vaporizers | 3 | 2015 | 62 | 0.220 |
Why?
| | Conjunctivitis, Allergic | 1 | 2004 | 4 | 0.220 |
Why?
| | Alternaria | 2 | 2002 | 9 | 0.220 |
Why?
| | Immunoglobulin G | 2 | 2025 | 892 | 0.220 |
Why?
| | Heartburn | 1 | 2024 | 12 | 0.210 |
Why?
| | Cytokines | 3 | 2016 | 2069 | 0.210 |
Why?
| | Gastroesophageal Reflux | 2 | 2024 | 237 | 0.210 |
Why?
| | Anesthetics, Local | 1 | 2005 | 104 | 0.210 |
Why?
| | Serum Sickness | 1 | 2004 | 4 | 0.210 |
Why?
| | Analgesia | 1 | 2005 | 106 | 0.210 |
Why?
| | Syphilis | 1 | 2004 | 38 | 0.210 |
Why?
| | Antigens, Bacterial | 2 | 2002 | 126 | 0.210 |
Why?
| | Adverse Drug Reaction Reporting Systems | 1 | 2004 | 81 | 0.200 |
Why?
| | Exanthema | 1 | 2004 | 86 | 0.200 |
Why?
| | Bioterrorism | 1 | 2004 | 31 | 0.200 |
Why?
| | Administration, Inhalation | 3 | 2016 | 571 | 0.200 |
Why?
| | Dopamine Uptake Inhibitors | 1 | 2004 | 59 | 0.200 |
Why?
| | Bupropion | 1 | 2004 | 48 | 0.200 |
Why?
| | Child | 10 | 2025 | 22738 | 0.200 |
Why?
| | Cockroaches | 1 | 2003 | 23 | 0.200 |
Why?
| | Geography | 1 | 2024 | 187 | 0.200 |
Why?
| | Registries | 7 | 2025 | 2410 | 0.200 |
Why?
| | Consensus | 1 | 2025 | 478 | 0.190 |
Why?
| | Research Design | 1 | 2009 | 1139 | 0.190 |
Why?
| | Glycoproteins | 2 | 2002 | 354 | 0.190 |
Why?
| | Signal Transduction | 2 | 2016 | 5223 | 0.190 |
Why?
| | Recurrence | 2 | 2017 | 1139 | 0.190 |
Why?
| | Lolium | 1 | 2002 | 2 | 0.190 |
Why?
| | Poaceae | 1 | 2002 | 37 | 0.180 |
Why?
| | Age of Onset | 1 | 2024 | 557 | 0.180 |
Why?
| | Interferon-gamma | 3 | 2016 | 784 | 0.180 |
Why?
| | Neisseria meningitidis | 1 | 2002 | 23 | 0.180 |
Why?
| | Pulmonary Atelectasis | 1 | 2002 | 15 | 0.180 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2022 | 116 | 0.180 |
Why?
| | Meningococcal Vaccines | 1 | 2002 | 57 | 0.170 |
Why?
| | Polysaccharides, Bacterial | 1 | 2002 | 69 | 0.170 |
Why?
| | Vaccines, Synthetic | 1 | 2002 | 137 | 0.170 |
Why?
| | Bacterial Outer Membrane Proteins | 1 | 2002 | 62 | 0.170 |
Why?
| | Adrenal Insufficiency | 1 | 2021 | 31 | 0.170 |
Why?
| | Clinical Trials as Topic | 4 | 2011 | 1062 | 0.170 |
Why?
| | Tuberculin | 1 | 2001 | 8 | 0.170 |
Why?
| | Hypersensitivity, Delayed | 1 | 2001 | 29 | 0.170 |
Why?
| | Tuberculin Test | 1 | 2001 | 36 | 0.170 |
Why?
| | Bronchodilator Agents | 1 | 2022 | 187 | 0.160 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2025 | 364 | 0.160 |
Why?
| | Fluticasone-Salmeterol Drug Combination | 2 | 2010 | 7 | 0.160 |
Why?
| | Reference Values | 4 | 2007 | 798 | 0.160 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2001 | 127 | 0.150 |
Why?
| | Receptors, Leukotriene | 2 | 2016 | 13 | 0.150 |
Why?
| | Algorithms | 4 | 2020 | 1850 | 0.150 |
Why?
| | Lung | 2 | 2007 | 4116 | 0.140 |
Why?
| | Drug Combinations | 2 | 2010 | 396 | 0.140 |
Why?
| | Histamine | 2 | 2011 | 52 | 0.140 |
Why?
| | Chickenpox Vaccine | 1 | 1999 | 76 | 0.140 |
Why?
| | Tosyl Compounds | 1 | 1998 | 17 | 0.140 |
Why?
| | STAT1 Transcription Factor | 2 | 2016 | 66 | 0.140 |
Why?
| | Theophylline | 1 | 1998 | 41 | 0.140 |
Why?
| | Aldehyde Oxidoreductases | 1 | 2018 | 28 | 0.140 |
Why?
| | Bacterial Capsules | 2 | 2012 | 33 | 0.140 |
Why?
| | Lamiaceae | 1 | 1997 | 2 | 0.130 |
Why?
| | Artemisia | 1 | 1997 | 4 | 0.130 |
Why?
| | Plants, Medicinal | 1 | 1997 | 23 | 0.130 |
Why?
| | Meteorological Concepts | 1 | 1997 | 6 | 0.130 |
Why?
| | Mycobacterium tuberculosis | 1 | 2001 | 318 | 0.130 |
Why?
| | Drug Therapy, Combination | 3 | 2023 | 1044 | 0.130 |
Why?
| | Spores, Fungal | 1 | 1997 | 23 | 0.130 |
Why?
| | Air Microbiology | 1 | 1997 | 37 | 0.130 |
Why?
| | Primary Health Care | 1 | 2008 | 1736 | 0.130 |
Why?
| | Leukocyte Count | 3 | 2025 | 318 | 0.130 |
Why?
| | Lymphocytosis | 1 | 1997 | 12 | 0.130 |
Why?
| | Benzamides | 1 | 2018 | 226 | 0.130 |
Why?
| | Cohort Studies | 5 | 2025 | 6032 | 0.120 |
Why?
| | Common Variable Immunodeficiency | 1 | 1997 | 26 | 0.120 |
Why?
| | Pyrroles | 1 | 2018 | 220 | 0.120 |
Why?
| | Leukotrienes | 1 | 2016 | 28 | 0.120 |
Why?
| | Aging | 1 | 2007 | 1973 | 0.120 |
Why?
| | Molecular Targeted Therapy | 2 | 2017 | 440 | 0.120 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 1997 | 100 | 0.120 |
Why?
| | Allergists | 1 | 2016 | 13 | 0.120 |
Why?
| | Interleukin-4 | 3 | 2013 | 207 | 0.120 |
Why?
| | Bacterial Toxins | 1 | 1997 | 108 | 0.120 |
Why?
| | Arthritis, Rheumatoid | 1 | 2025 | 1180 | 0.120 |
Why?
| | Comorbidity | 4 | 2024 | 1662 | 0.120 |
Why?
| | Interleukins | 2 | 2013 | 248 | 0.120 |
Why?
| | Venoms | 1 | 2016 | 22 | 0.120 |
Why?
| | Administration, Oral | 2 | 2025 | 867 | 0.120 |
Why?
| | Leukoencephalopathy, Progressive Multifocal | 1 | 2016 | 38 | 0.110 |
Why?
| | Canada | 1 | 2017 | 432 | 0.110 |
Why?
| | Herpesvirus 3, Human | 1 | 1999 | 343 | 0.110 |
Why?
| | Insecta | 1 | 2016 | 71 | 0.110 |
Why?
| | Anti-Inflammatory Agents | 2 | 2012 | 478 | 0.110 |
Why?
| | Epinephrine | 1 | 2016 | 158 | 0.110 |
Why?
| | Leukocytes, Mononuclear | 1 | 1998 | 574 | 0.110 |
Why?
| | Drugs, Generic | 1 | 2015 | 28 | 0.110 |
Why?
| | Cardiac Tamponade | 1 | 1994 | 15 | 0.110 |
Why?
| | Bronchial Diseases | 1 | 1994 | 38 | 0.110 |
Why?
| | Papilloma | 1 | 1994 | 49 | 0.110 |
Why?
| | Tumor Virus Infections | 1 | 1994 | 51 | 0.110 |
Why?
| | Pentamidine | 1 | 1994 | 3 | 0.110 |
Why?
| | Gallium Radioisotopes | 1 | 1994 | 16 | 0.110 |
Why?
| | Phosphorylation | 2 | 2016 | 1708 | 0.100 |
Why?
| | Pneumonia, Pneumocystis | 1 | 1994 | 34 | 0.100 |
Why?
| | Papillomaviridae | 1 | 1994 | 116 | 0.100 |
Why?
| | Aerosols | 3 | 2001 | 145 | 0.100 |
Why?
| | Basophils | 2 | 2013 | 52 | 0.100 |
Why?
| | Animals | 7 | 2017 | 38100 | 0.100 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2002 | 849 | 0.100 |
Why?
| | Cluster Analysis | 2 | 2025 | 501 | 0.100 |
Why?
| | Bronchiectasis | 1 | 1994 | 115 | 0.100 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 1994 | 130 | 0.100 |
Why?
| | Pharmaceutical Preparations | 1 | 2015 | 171 | 0.100 |
Why?
| | Guidelines as Topic | 1 | 2015 | 268 | 0.090 |
Why?
| | Cardiovascular Diseases | 1 | 2025 | 2190 | 0.090 |
Why?
| | Evidence-Based Medicine | 1 | 2017 | 740 | 0.090 |
Why?
| | Drug Resistance | 1 | 2013 | 145 | 0.090 |
Why?
| | Salmonella Vaccines | 1 | 2012 | 2 | 0.090 |
Why?
| | Bacteriophage phi X 174 | 1 | 2012 | 5 | 0.090 |
Why?
| | Rabies Vaccines | 1 | 2012 | 3 | 0.090 |
Why?
| | Longitudinal Studies | 3 | 2025 | 2967 | 0.090 |
Why?
| | Olfaction Disorders | 1 | 2013 | 70 | 0.090 |
Why?
| | Haemophilus Vaccines | 1 | 2012 | 29 | 0.090 |
Why?
| | T-Lymphocytes | 2 | 2016 | 1997 | 0.090 |
Why?
| | Receptors, Histamine | 1 | 2011 | 2 | 0.090 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2011 | 26 | 0.090 |
Why?
| | Immunity, Humoral | 1 | 2012 | 118 | 0.090 |
Why?
| | Therapeutic Equivalency | 2 | 2025 | 31 | 0.090 |
Why?
| | History, 19th Century | 1 | 2011 | 63 | 0.090 |
Why?
| | Pneumococcal Vaccines | 1 | 2012 | 129 | 0.090 |
Why?
| | Salmeterol Xinafoate | 1 | 2010 | 20 | 0.080 |
Why?
| | Fluticasone | 1 | 2010 | 53 | 0.080 |
Why?
| | Health Surveys | 2 | 2012 | 520 | 0.080 |
Why?
| | Retrospective Studies | 6 | 2024 | 17322 | 0.080 |
Why?
| | Respiratory Mucosa | 1 | 2013 | 322 | 0.080 |
Why?
| | Papillomavirus Infections | 1 | 1994 | 344 | 0.080 |
Why?
| | History, 20th Century | 1 | 2011 | 328 | 0.080 |
Why?
| | Phenotype | 2 | 2017 | 3170 | 0.080 |
Why?
| | Cyclopropanes | 1 | 2010 | 84 | 0.080 |
Why?
| | Medication Adherence | 1 | 2014 | 540 | 0.080 |
Why?
| | Receptors, IgG | 1 | 2009 | 77 | 0.080 |
Why?
| | Injections, Subcutaneous | 2 | 2025 | 170 | 0.070 |
Why?
| | Congresses as Topic | 1 | 2011 | 224 | 0.070 |
Why?
| | Chemokine CCL26 | 1 | 2009 | 10 | 0.070 |
Why?
| | Chemokines, CC | 1 | 2009 | 33 | 0.070 |
Why?
| | Sulfides | 1 | 2010 | 92 | 0.070 |
Why?
| | Bone Marrow | 2 | 2013 | 307 | 0.070 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2009 | 82 | 0.070 |
Why?
| | United States Food and Drug Administration | 1 | 2009 | 208 | 0.070 |
Why?
| | Case-Control Studies | 1 | 2016 | 3634 | 0.070 |
Why?
| | Interleukin-13 | 1 | 2009 | 146 | 0.070 |
Why?
| | Clinical Competence | 1 | 2016 | 1247 | 0.070 |
Why?
| | Antibodies, Viral | 2 | 2025 | 674 | 0.070 |
Why?
| | Adenosine | 1 | 2009 | 255 | 0.070 |
Why?
| | Kartagener Syndrome | 1 | 2007 | 31 | 0.070 |
Why?
| | Vasodilator Agents | 1 | 2009 | 330 | 0.070 |
Why?
| | Bronchiolitis Obliterans | 1 | 2007 | 61 | 0.060 |
Why?
| | Recombinant Fusion Proteins | 1 | 2010 | 666 | 0.060 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2013 | 1146 | 0.060 |
Why?
| | Infant, Newborn | 1 | 2018 | 6464 | 0.060 |
Why?
| | Health Status | 1 | 2012 | 835 | 0.060 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2009 | 552 | 0.060 |
Why?
| | Transforming Growth Factor beta | 1 | 2009 | 474 | 0.060 |
Why?
| | Flushing | 1 | 2005 | 2 | 0.060 |
Why?
| | Administration, Topical | 1 | 2005 | 155 | 0.060 |
Why?
| | Penicillin G | 1 | 2004 | 7 | 0.050 |
Why?
| | Histamine H1 Antagonists | 1 | 2004 | 24 | 0.050 |
Why?
| | Healthy Volunteers | 1 | 2025 | 219 | 0.050 |
Why?
| | New Zealand | 1 | 2025 | 55 | 0.050 |
Why?
| | Area Under Curve | 1 | 2025 | 332 | 0.050 |
Why?
| | Acute Disease | 1 | 2008 | 1036 | 0.050 |
Why?
| | Mutation | 1 | 2016 | 4090 | 0.050 |
Why?
| | Methylprednisolone Hemisuccinate | 1 | 2004 | 1 | 0.050 |
Why?
| | Clostridium botulinum | 1 | 2004 | 4 | 0.050 |
Why?
| | Anthrax Vaccines | 1 | 2004 | 7 | 0.050 |
Why?
| | Arenaviruses, New World | 1 | 2004 | 9 | 0.050 |
Why?
| | Dependovirus | 1 | 2025 | 78 | 0.050 |
Why?
| | Placebos | 2 | 2018 | 193 | 0.050 |
Why?
| | Biomedical Research | 1 | 2011 | 719 | 0.050 |
Why?
| | Infant | 1 | 2018 | 10089 | 0.050 |
Why?
| | Smallpox Vaccine | 1 | 2004 | 23 | 0.050 |
Why?
| | China | 1 | 2025 | 273 | 0.050 |
Why?
| | Diarrhea | 1 | 2005 | 193 | 0.050 |
Why?
| | Membrane Proteins | 1 | 2010 | 1166 | 0.050 |
Why?
| | Yersinia pestis | 1 | 2004 | 45 | 0.050 |
Why?
| | Bacterial Vaccines | 1 | 2004 | 63 | 0.050 |
Why?
| | Francisella tularensis | 1 | 2004 | 33 | 0.050 |
Why?
| | Headache | 1 | 2004 | 152 | 0.050 |
Why?
| | Insect Control | 1 | 2003 | 18 | 0.050 |
Why?
| | Food Contamination | 1 | 2003 | 33 | 0.050 |
Why?
| | Genetic Vectors | 1 | 2025 | 335 | 0.050 |
Why?
| | Child, Preschool | 1 | 2018 | 11866 | 0.050 |
Why?
| | Classification | 1 | 2003 | 44 | 0.050 |
Why?
| | Adjuvants, Immunologic | 1 | 2004 | 244 | 0.050 |
Why?
| | Disease Transmission, Infectious | 1 | 2003 | 69 | 0.050 |
Why?
| | Viral Vaccines | 1 | 2004 | 107 | 0.050 |
Why?
| | Multimorbidity | 1 | 2023 | 65 | 0.050 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2023 | 98 | 0.050 |
Why?
| | Pain Measurement | 1 | 2005 | 562 | 0.050 |
Why?
| | Antigens, Dermatophagoides | 1 | 2002 | 10 | 0.050 |
Why?
| | Disaster Planning | 1 | 2004 | 103 | 0.050 |
Why?
| | Genetic Therapy | 1 | 2025 | 316 | 0.050 |
Why?
| | Insurance Claim Review | 1 | 2022 | 83 | 0.050 |
Why?
| | Immunoglobulin Isotypes | 1 | 2002 | 36 | 0.040 |
Why?
| | Aspergillosis, Allergic Bronchopulmonary | 1 | 2002 | 11 | 0.040 |
Why?
| | Menstruation | 1 | 2002 | 40 | 0.040 |
Why?
| | Proportional Hazards Models | 1 | 2025 | 1330 | 0.040 |
Why?
| | Drug Tolerance | 1 | 2002 | 99 | 0.040 |
Why?
| | Referral and Consultation | 1 | 2008 | 868 | 0.040 |
Why?
| | Recombinant Proteins | 1 | 2025 | 1368 | 0.040 |
Why?
| | Time Factors | 2 | 2010 | 7133 | 0.040 |
Why?
| | Mycobacterium avium | 1 | 2001 | 21 | 0.040 |
Why?
| | Lung Neoplasms | 1 | 1994 | 2667 | 0.040 |
Why?
| | Antibodies, Bacterial | 1 | 2002 | 147 | 0.040 |
Why?
| | Aged, 80 and over | 1 | 2013 | 8346 | 0.040 |
Why?
| | Consumer Product Safety | 1 | 2002 | 80 | 0.040 |
Why?
| | Plant Extracts | 1 | 2002 | 188 | 0.040 |
Why?
| | Multivariate Analysis | 1 | 2024 | 1547 | 0.040 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2007 | 920 | 0.040 |
Why?
| | Ultrasonic Therapy | 1 | 2000 | 16 | 0.040 |
Why?
| | Health Care Costs | 1 | 2023 | 425 | 0.040 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2004 | 430 | 0.040 |
Why?
| | Respiratory Mechanics | 1 | 2000 | 74 | 0.040 |
Why?
| | Neutrophils | 2 | 2017 | 1125 | 0.040 |
Why?
| | In Vitro Techniques | 1 | 2001 | 1049 | 0.040 |
Why?
| | Databases, Factual | 1 | 2025 | 1491 | 0.040 |
Why?
| | Inflammation | 1 | 2010 | 2883 | 0.040 |
Why?
| | Phenylcarbamates | 1 | 1998 | 5 | 0.040 |
Why?
| | Leukotriene Antagonists | 1 | 1998 | 24 | 0.030 |
Why?
| | Uricosuric Agents | 1 | 1998 | 2 | 0.030 |
Why?
| | Probenecid | 1 | 1998 | 8 | 0.030 |
Why?
| | Bronchoconstrictor Agents | 1 | 2018 | 14 | 0.030 |
Why?
| | S-Nitrosoglutathione | 1 | 2018 | 8 | 0.030 |
Why?
| | Fluorescent Antibody Technique | 1 | 1999 | 365 | 0.030 |
Why?
| | Methacholine Chloride | 1 | 2018 | 51 | 0.030 |
Why?
| | Pregnancy | 1 | 2011 | 7215 | 0.030 |
Why?
| | Pokeweed Mitogens | 1 | 1998 | 6 | 0.030 |
Why?
| | Phytohemagglutinins | 1 | 1998 | 29 | 0.030 |
Why?
| | Interleukin-4 Receptor alpha Subunit | 1 | 2018 | 9 | 0.030 |
Why?
| | Public Health | 1 | 2003 | 574 | 0.030 |
Why?
| | Concanavalin A | 1 | 1998 | 72 | 0.030 |
Why?
| | Cells, Cultured | 2 | 2013 | 4151 | 0.030 |
Why?
| | Proof of Concept Study | 1 | 2018 | 89 | 0.030 |
Why?
| | Immunocompetence | 1 | 1998 | 46 | 0.030 |
Why?
| | Respiratory Function Tests | 2 | 2010 | 544 | 0.030 |
Why?
| | Mitogens | 1 | 1998 | 55 | 0.030 |
Why?
| | Equipment Design | 2 | 2015 | 525 | 0.030 |
Why?
| | Sodium Dodecyl Sulfate | 1 | 1997 | 25 | 0.030 |
Why?
| | Pollen | 1 | 1997 | 17 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 2 | 2020 | 2770 | 0.030 |
Why?
| | Cladosporium | 1 | 1997 | 1 | 0.030 |
Why?
| | Mitosporic Fungi | 1 | 1997 | 6 | 0.030 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 1997 | 50 | 0.030 |
Why?
| | Organophosphonates | 1 | 1998 | 95 | 0.030 |
Why?
| | Evaluation Studies as Topic | 1 | 1997 | 164 | 0.030 |
Why?
| | Cross Reactions | 1 | 1997 | 130 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2010 | 5428 | 0.030 |
Why?
| | Cystic Fibrosis | 1 | 2007 | 1163 | 0.030 |
Why?
| | Administration, Intravenous | 1 | 2018 | 172 | 0.030 |
Why?
| | Colony Count, Microbial | 1 | 1997 | 89 | 0.030 |
Why?
| | Herpes Simplex | 1 | 1998 | 99 | 0.030 |
Why?
| | Immunization | 1 | 1999 | 375 | 0.030 |
Why?
| | Immunoblotting | 1 | 1997 | 295 | 0.030 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1997 | 331 | 0.030 |
Why?
| | Drug Interactions | 1 | 1998 | 405 | 0.030 |
Why?
| | Superantigens | 1 | 1997 | 70 | 0.030 |
Why?
| | Enterotoxins | 1 | 1997 | 89 | 0.030 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 1998 | 237 | 0.030 |
Why?
| | Prognosis | 1 | 2005 | 4329 | 0.030 |
Why?
| | JC Virus | 1 | 2016 | 23 | 0.030 |
Why?
| | Surveys and Questionnaires | 1 | 2009 | 6084 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 2018 | 610 | 0.030 |
Why?
| | Patient Acceptance of Health Care | 1 | 2022 | 883 | 0.030 |
Why?
| | Workflow | 1 | 2017 | 183 | 0.030 |
Why?
| | Cross-Sectional Studies | 2 | 2023 | 5921 | 0.030 |
Why?
| | Biopsy | 2 | 2011 | 1082 | 0.030 |
Why?
| | Gene Expression Regulation | 2 | 2016 | 2601 | 0.030 |
Why?
| | Pharmacokinetics | 1 | 2015 | 33 | 0.030 |
Why?
| | Lymphocyte Activation | 1 | 1999 | 1133 | 0.030 |
Why?
| | IgA Deficiency | 1 | 1994 | 5 | 0.030 |
Why?
| | Pericarditis | 1 | 1994 | 11 | 0.030 |
Why?
| | Seasons | 1 | 1997 | 538 | 0.030 |
Why?
| | Indoles | 1 | 1998 | 507 | 0.030 |
Why?
| | Sulfonamides | 1 | 1998 | 583 | 0.030 |
Why?
| | Internationality | 1 | 2015 | 156 | 0.030 |
Why?
| | Radionuclide Imaging | 1 | 1994 | 116 | 0.030 |
Why?
| | Self Report | 1 | 2018 | 875 | 0.030 |
Why?
| | Constriction, Pathologic | 1 | 1994 | 249 | 0.030 |
Why?
| | Transcriptional Activation | 1 | 2016 | 372 | 0.030 |
Why?
| | Anti-Bacterial Agents | 1 | 2004 | 1925 | 0.030 |
Why?
| | Receptors, Interleukin-5 | 1 | 2013 | 4 | 0.020 |
Why?
| | Suppressor of Cytokine Signaling Proteins | 1 | 2013 | 20 | 0.020 |
Why?
| | Viral Load | 1 | 2016 | 526 | 0.020 |
Why?
| | Hypersensitivity, Immediate | 1 | 2013 | 41 | 0.020 |
Why?
| | Risk Factors | 1 | 2008 | 10916 | 0.020 |
Why?
| | Arachidonic Acid | 1 | 2013 | 102 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 778 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 1998 | 1218 | 0.020 |
Why?
| | Flow Cytometry | 1 | 1997 | 1165 | 0.020 |
Why?
| | Disease Management | 1 | 2017 | 653 | 0.020 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2013 | 337 | 0.020 |
Why?
| | Staphylococcus aureus | 1 | 1997 | 453 | 0.020 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 1994 | 238 | 0.020 |
Why?
| | Histocytochemistry | 1 | 2011 | 78 | 0.020 |
Why?
| | Efficiency | 1 | 2012 | 103 | 0.020 |
Why?
| | Nasal Mucosa | 1 | 2011 | 112 | 0.020 |
Why?
| | Eosinophil Cationic Protein | 1 | 2010 | 9 | 0.020 |
Why?
| | Interleukin-5 Receptor alpha Subunit | 1 | 2010 | 6 | 0.020 |
Why?
| | Autoimmune Diseases | 1 | 1994 | 469 | 0.020 |
Why?
| | Prospective Studies | 1 | 2023 | 8075 | 0.020 |
Why?
| | Lymphopenia | 1 | 2010 | 62 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2011 | 408 | 0.020 |
Why?
| | Models, Biological | 1 | 1997 | 1764 | 0.020 |
Why?
| | Cell Count | 1 | 2010 | 319 | 0.020 |
Why?
| | Cats | 1 | 2009 | 234 | 0.020 |
Why?
| | Occupational Health | 1 | 2012 | 213 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2009 | 318 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2010 | 423 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2016 | 3551 | 0.020 |
Why?
| | Sleep Wake Disorders | 1 | 2012 | 314 | 0.020 |
Why?
| | Up-Regulation | 1 | 2009 | 848 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2009 | 1300 | 0.020 |
Why?
| | Exercise Test | 1 | 2009 | 630 | 0.020 |
Why?
| | Emotions | 1 | 2012 | 577 | 0.010 |
Why?
| | Interleukin-6 | 1 | 2010 | 779 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2009 | 2028 | 0.010 |
Why?
| | ROC Curve | 1 | 2005 | 618 | 0.010 |
Why?
| | Brain | 1 | 2016 | 2969 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2013 | 5992 | 0.010 |
Why?
| | Apoptosis | 1 | 2010 | 2443 | 0.010 |
Why?
| | Spectrophotometry | 1 | 2001 | 58 | 0.010 |
Why?
| | Rheology | 1 | 2001 | 94 | 0.010 |
Why?
| | Sodium Chloride | 1 | 2001 | 138 | 0.010 |
Why?
| | Particle Size | 1 | 2001 | 381 | 0.010 |
Why?
| | Cytosine | 1 | 1998 | 49 | 0.010 |
Why?
| | Organophosphorus Compounds | 1 | 1998 | 84 | 0.010 |
Why?
| | Mice | 1 | 2013 | 18357 | 0.010 |
Why?
|
|
Katial's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|